Helios and Matheson Analytics Inc (OTCMKTS:HMNY)just announced that its board of directors has formed a strategic review committee, composed entirely of the Company’s independent directors, to identify, review and explore all strategic and financial alternatives for the Company, including a sale of the Company in its entirety, a sale of substantially all of the Company’s assets including MoviePass, Moviefone and MoviePass Films, a business reorganization or one or more other extraordinary corporate transactions, together with the assumption or settlement of the Company’s liabilities in connection with any of these alternatives.

According to the release, “the Company requests that all bona fide transaction proposals and expressions of interest be directed to the Committee at There can be no assurance that the Committee’s review process will result in any transaction.”

Helios and Matheson Analytics Inc (OTCMKTS:HMNY) trumpets itself as a company that provides a range of information technology (IT) solutions to Fortune 1000 companies and other organizations in the United States.

The company’s services include application value management, application development, integration, independent validation, infrastructure, information management, and analytics services. Its clients operate in various industries, including banking, financial services, automotive, insurance, and healthcare. 

The company was formerly known as Helios and Matheson Information Technology Inc. and changed its name to Helios and Matheson Analytics Inc. in May 2013. Helios and Matheson Analytics Inc. was founded in 1982 and is headquartered in New York, New York.

MoviePass Inc. is a marketing technology platform enhancing the exploration of film and the moviegoing experience. As a premier movie-theater subscription service, MoviePass provides film enthusiasts the ability to attend select new movies in theaters. The service is now accepted at theaters everywhere in the U.S. Visit us at

Recent action has seen 24% piled on for shareholders of the name during the trailing month. In addition, the stock has seen a growing influx of trading interest, with the stock’s recent average trading volume running above 420% beyond its prior sustained average level. 

HMNY has virtually no cash on the books, which stands against virtually no total current liabilities. HMNY is pulling in trailing 12-month revenues of $232.3M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 401.8%.

Terra Tech Corp (OTCMKTS:TRTC)ripped to the upside yesterday as the stock reacted to news of a new share repurchase program now in play for the company. According to company communications, TRTC plans to repurchase up to $20,000,000 of the Company’s common stock. 

That news helped to power buying in the stock on high volume in a breakout from its recent weakness. According to the release, “This share buyback program is in addition to the previously announced purchase of shares of the Company’s common stock in connection with the settlement of litigation with members of the Vande Vrede family. The Company expects to receive approximately $36,000,000 upon the closing of previously announced asset sales. Repurchases may be made at management’s discretion from time to time on the open market or through privately negotiated transactions. The repurchase program has no time limit and may be suspended for periods or discontinued at any time. Any shares acquired will be held by the Company as treasury shares. As of August 2, 2019, the Company had 109,278,898 shares of common stock outstanding.”

Terra Tech Corp (OTCMKTS:TRTC) has positioned itself in the cannabis space as a company that engages in the design, marketing, and sale of hydroponic equipment with proprietary technology to create sustainable solutions for the cultivation of indoor agriculture in Newport Beach and Irvine, California.

TRTC operates through two segments, Hydroponic Produce and Cannabis Products. The company offers environmental controllers and timers; ballasts; bulbs; reflectors; nutrients; and portable hydroponic trailers and The Big Bud and Little Bud, which are custom fabricated proprietary cultivation systems for horticulture enthusiasts, local urban farmers, and greenhouse growers

Additionally, TRTC operates as a retail seller of hydroponic produce, herbs, and floral products, which are distributed in the Midwest and the Northeast United States; and produces and sells a line of cannabis flowers and cigarettes, as well as a line of cannabis pure concentrates, including oils, waxes, shatters, and clears to dispensaries in California.

The company operates through multiple subsidiary businesses, including Blum, IVXX Inc., Edible Gardens, MediFarm LLC and GrowOp Technology.

Blum’s retail medical cannabis facilities focus on providing the highest quality medical cannabis to patients who are looking for alternative treatments for their chronic medical conditions. Blum offers a broad selection of medical cannabis products including; flowers, concentrates and edibles through its Oakland, CA and multiple Nevada locations.

Chief Executive Officer, Derek Peterson, said, “We believe that Terra Tech’s current market value does not reflect the underlying value of its business and future prospects, and that implementing a share buyback program is the best way we can return value to shareholders. We have several growth initiatives in the pipeline and are engaged in a fundamental restructuring to improve profitability and build value for our shareholders. The share repurchase program is supported by our continued focus on building a stronger, more efficient business based around premium quality, recognizable brands.”

If you’re long this stock, then you’re liking how the stock has responded to the announcement. TRTC shares have been moving higher over the past week overall, pushing about 25% to the upside on above average trading volume.

Terra Tech Corp (OTCMKTS:TRTC) managed to rope in revenues totaling $10.4M in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of 19%, as compared to year-ago data in comparable terms. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($1.9M against $8.6M, respectively).

NaturalShrimp Inc (OTCMKTS:SHMP)has been strengthening and positive catalysts continue to pile up. Helping to further flesh out the narrative, the company just announced with Hydrenesis that they have signed a 5-year agreement with Hanilu Farms of Indiana to operate their Hydrogas water treatment system.

According to the release, “Hanilu Farms came to us with the goal of reducing their mortality and feed rate while increasing grow out stock that have limited the full potential of indoor barramundi aquaculture to date. The international aquaculture industry is growing annually. The finfish industry is one of the most developed industries and are generally adopters of new technologies. The Barramundi industry has been one of the major targets for Hydrenesis and Natural Aquatic Systems for this proof of concept work. This new agreement with Hanilu Farms provides another milestone in testing our platform to achieve a more efficient treatment solution for indoor Barramundi.”

Even in light of this news, SHMP has had a rough past week of trading action, with shares sinking something like -3% in that time. That said, chart support is nearby and we may be in the process of constructing a nice setup for some movement back the other way.

SHMP had no reported sales in its last quarterly financial data. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($818K against $4.8M, respectively).

NaturalShrimp Inc (OTCMKTS:SHMP) bills itself as a global shrimp farming company that is developing a technology to produce fresh, gourmet-grade shrimp reliably and economically in an indoor, re-circulating, saltwater facility.

Its eco-friendly, bio-secure design does not rely on ocean water, but rather recreates the natural ocean environment allowing for high-density production which can be replicated anywhere in the world.

Gerald Easterling, President of NaturalShrimp, commented: “We continue to expand our aquaculture capabilities after our initial focus of bringing shrimp to market, and with this additional agreement, we are poised to expand our capabilities to indoor farm raised barramundi as well.”